POPULARITY
“There have been many changes since the '70s that have shaped the nurse's role in administering chemo, and in supporting patients. The major change early on was the transition from that of nurses mixing chemo to that of pharmacists. Regulatory agencies like NIOSH and OSHA defined chemotherapy as hazardous drugs, and professional organizations became involved, leading to the publication of the joint ASCO and ONS Standards of Safe Handling,” ONS member Scarlott Mueller, MPH, RN, FAAN, secretary of the American Cancer Society Cancer Action Network Board and member of the Oncology Nursing Foundation Capital Campaign Cabinet, told Darcy Burbage, DNP, RN, AOCN®, CBCN®, ONS member and chair of the ONS 50th Anniversary Committee during a conversation about the evolution of chemotherapy treatment. Along with Mueller, Burbage spoke with John Hillson, DNP, NP, Mary Anderson, BSN, RN, OCN®, and Kathleen Shannon-Dorcy, PhD, RN, FAAN, about the changes in radiation, oral chemotherapy, and cellular therapy treatments they have witnessed during their careers. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Episode Notes This episode is not eligible for NCPD. ONS Podcast™ episodes: 50th anniversary series Episode 330: Stay Up to Date on Safe Handling of Hazardous Drugs Episode 59: Blood and Marrow Transplant Nursing Episode 16: Navigating the Challenges of Oral Chemotherapy ONS Voice article:Safe Handling—We've Come a Long Way, Baby! ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) Hematopoietic Stem Cell Transplantation: A Manual for Nursing Practice (third edition) Oncology Nurse Navigation: Delivering Patient-Centered Care Across the Continuum (second edition) Safe Handling of Hazardous Drugs (fourth edition) ONS courses: ONS Hematopoietic Stem Cell Transplantation™ ONS/ONCC® Chemotherapy Immunotherapy Certificate™ ONS/ONCC® Radiation Therapy Certificate™ Safe Handling Basics Oral Anticancer Medication Toolkit Oral Anticancer Medication Care Compass Patient education guides created as a collaboration between ONS, HOPA, NCODA, and the Association of Community Cancer Centers: IV Cancer Treatment Education Sheets Oral Chemotherapy Education Sheets Connie Henke Yarbro Oncology Nursing History Center To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode Hillson: “I remember as a new grad, from back in '98, walking up to the oncology floor. We had patients with pink labels on the chart and that was the radiation oncology service. I hadn't heard of such a thing before. … I'd gone through nursing school and hospital orientation and unit orientation without ever hearing of these therapies. At the time, both the management and the union had no interest in specialist nurses, and the really weren't any books that were targeting the role. And it was very isolating and frightening. I was very glad to find ONS when I moved to the U.S. Right now, the Oncology Nursing Society Manual for Radiation Oncology, Nursing Practice, and Education, it's in its fifth edition and a sixth is underway. There's nothing else like it. Most books are very much geared towards other professions.” TS 5:34 Mueller: “We mixed our chemo in a very small medication room on the unit, under a horizontal laminar flow hood, which we later discovered should have been a vertical laminar flow hood. Initially, we did not use any personal protective equipment. I remember mixing drugs like bleomycin and getting a little spray that from the vial onto my face. And to this day, I still have a few facial blemishes from that.” TS 14:28 Anderson: “As the increasing number of these actionable mutations continue to grow, so will the number of oral anticancer medications that patients are going to be taking. And we are already seeing that there's multiple combination regimens and complex schedules that the patients have to take. So this role the oral oncolytic nurse and the nursing role, like you said, it cannot be owned by one individual or discipline. So it's not a pharmacist; the pharmacies aren't owning this. The nurses are not owning this. It takes a village.” TS 32:12 Shannon-Dorcy: Then as immunotherapy comes into the picture, we start to learn about [cytokine release syndrome]. All of a sudden, we had no concept that this was a deadly consequence. ONS was on the front lines, convening people across the country together so we could speak to the investigative work with science and find ways that we could intervene, how we can look for signs of it early on with handwriting testing.” TS 39:58
“You can give someone a survivorship care plan, but just giving them doesn't mean that it's going to happen. Maybe there's no information about family history. Or maybe there's information and there's quite a bit of family history, but there's nothing that says, ‘Oh, they were ever had genetic testing,' or ‘Oh, they were ever referred.' So the intent is so good because it's to really take that time out when they're through with active treatment and, you know, try to help give the patient some guidance as to what to expect down the line,” Suzanne Mahon, DNS, RN, AOCN®, AGN-BC, FAAN, professor emeritus at Saint Louis University in Missouri, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about breast cancer survivorship. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by March 14, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to breast cancer survivorship. Episode Notes Complete this evaluation for free NCPD. Previous ONS Podcast™ site-specific episodes: Episode 350: Breast Cancer Treatment Considerations for Nurses Episode 348: Breast Cancer Diagnostic Considerations for Nurses Episode 345: Breast Cancer Screening, Detection, and Disparities ONS Voice articles: Breast Cancer Prevention, Screening, Diagnosis, Treatment, Side Effect, and Survivorship Considerations Improve Management of Common Symptoms for Breast Cancer Survivors Nursing Considerations for Breast Cancer Survivorship Care Sexual Considerations for Patients With Cancer ONS books: Breast Care Certification Review (second edition) Guide to Breast Care for Oncology Nurses ONS course: Breast Cancer Bundle ONS Learning Libraries: Breast Cancer Genomics and Precision Oncology Nurse Navigation Oral Anticancer Medication Survivorship ONS Guidelines™ and Symptom Interventions: Anxiety Cognitive Impairment Depression Fatigue Clinical Journal of Oncology Nursing article: Survivorship Care: More Than Checking a Box Clinical Journal of Oncology Nursing supplement: Survivorship Care American Cancer Society: Cancer Treatment and Survivorship Facts and Figures Survivorship: During and After Treatment Livestrong® Program at the YMCA National Comprehensive Cancer Network National Cancer Institute Breast Cancer—Patient Version To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “I think the biggest thing is to really communicate is that people are living with breast cancer for a long, long periods of time, and a lot of that with really good quality overall.” TS 4:07 “As a general rule, they're going to be seen by the breast surgeon probably every four to six months for a while. After about five years, a lot of times people are ready to say, ‘Okay, annually is okay.' And eventually they may let that drop off. But it also depends on did they have a mastectomy? Did they have breast conserving surgery? And then if they had reconstruction with an implant, how often do they see the plastic surgeon? Because they need to check integrity of the implant. So those schedules are really individualized.” TS 13:24 “When you think about long-term effects, I think you need to kind of think about that survivors can have both acute and long-term chronic effects. And a lot of that depends on the specifics of the treatment they had. I think as oncology nurses, we're used to, ‘We give you this chemotherapy or this agent, and these are the side effects.'” TS 15:36 “The diet issues are huge. And I think we are slow to refer to the dietician, you know, you can get them a couple of consults and because you're saying to them, ‘This is really important. We need you to lose weight or we need you to eat more of this.' Ideally, fruits and vegetables are going to be about half of your plate. And what's the difference between a whole grain and not, less processed foods, making sure that they're getting enough protein. And then once again, really kind of making sure that they're not taking a lot of supplements and extra stuff because we don't really understand all that fully and it could be harmful.” TS 34:53 “Breast cancer is a long, long journey, and I think you should never underestimate the real difference that nurses can make. I think they can ask those tough questions. And I think ask the questions that are important to patients that patients may be reluctant to ask. I think giving patients permission to talk about those less-talked-about symptoms and acknowledge that those symptoms are real and that there are some strategies to mitigate those symptoms.” TS 42:28
“This is what totally drives the treatment decisions, and that's why having that pathology report when the nurse is educating the patient is so important, because you can say, well, you have this kind of breast cancer, and this kind of breast cancer is generally treated this way,” Suzanne Mahon, DNS, RN, AOCN®, AGN-BC, FAAN, professor emeritus at Saint Louis University in Missouri, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about what oncology nurses need to know about breast cancer treatment. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 1.0 contact hours (including 15 minutes of pharmacotherapeutic content) of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by February 14, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to breast cancer treatment considerations. Episode Notes Complete this evaluation for free NCPD. Previous ONS Podcast™ site-specific episodes: ONS Voice articles: Episode 348: Breast Cancer Diagnostic Considerations for Nurses Episode 345: Breast Cancer Screening, Detection, and Disparities ONS Voice articles: An Oncology Nurse's Guide to Cascade Testing Breast Cancer Prevention, Screening, Diagnosis, Treatment, Side Effect, and Survivorship Considerations Learn How to Read a Germline Genomic Testing Report Learn How to Read a Somatic Biomarker Testing Report Sexual Considerations for Patients With Cancer ONS books: Breast Care Certification Review (second edition) Guide to Breast Care for Oncology Nurses ONS courses: Breast Cancer Bundle Breast Cancer: Treatment and Symptom Management ONS Biomarker Database results for breast cancer ONS Next-Generation Sequencing Sample Report ONS Learning Libraries: Breast Cancer Genomics and Precision Oncology American Cancer Society: Breast Cancer Facts and Figures Your Breast Pathology Report: Breast Cancer National Comprehensive Cancer Network National Cancer Institute Breast Cancer—Patient Version To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “Local treatment is typically going to consider some kind of surgery with or without radiation, depending on the surgery and the extent of the breast cancer. All women are going to have, and today when you use the word women, individuals assigned female at birth, they are the vast majority of individuals being treated for breast cancer, but for individuals assigned male at birth, there's not near as much research, but generally their treatment is very similar. So that's something to kind of keep in the back of your mind.” TS 2:39 “This is very confusing for patients because they're like, ‘Well, my friend at church had this and why am I getting this and why are they getting something different?' And that is because of the pathology report. So taking that time to explain that with a pathology, I think is really important.” TS 8:31 “When they see the breast surgeon, all individuals are going to have some kind of axillary evaluation. Now, hopefully it's going to be a sentinel lymph node. So they're going to, at the time of surgery, put a tracer and, you know, they're going to take out maybe one, two, three lymph nodes and hopefully, you know, there is not a lot of disease there. And if that's the case, they're kind of done with that. So the sentinel lymph node evaluation, it's really more to stage and provide that information, but it kind of sets the stage a lot of times for the other treatments selections. And I think people need to realize that this is important. This is a very important procedure.” TS 15:31 “Years ago, when women had a breast mass, they went to the OR and it was biopsied in a frozen section and if it was positive, they had a mastectomy. So women would wake up and they'd be feeling their chest because they're like, ‘What happened here?' And that is not great care. It doesn't give that woman any autonomy, but it was the best that could be done at that point. Now, with the diagnostic where we can do a needle biopsy, they can kind of stop and take a timeout and we can kind of clinically stage that.” TS 17:04 “For women that really desire breast-conserving therapy, they can anticipate that postoperatively at some point, they're going to have treatment to the entire breast, we typically call whole breast radiation, and then they may have a boost. Now, in many, many probably cases, that's going to be over five to six weeks, Monday through Friday. So the treatment itself doesn't take but a couple of minutes, but you have to get to the facility. And even though we streamline check-in processes and whatnot, you have to get undressed, you have to get positioned on the table. So it is a commitment, and it can be disruptive.” TS 24:49 “The hormone-blocking agents are going to be the cornerstone of all those treatments for anyone who has hormone receptor–positive breast cancer. So they are going to take these agents and as you said, they're probably going to take them for 5–10 years. It's quite the journey.” TS 32:33 “I think you need to be mindful that if someone has had germline testing and they've tested positive, they are not only worried about themselves, and they are worried about the rest of their family. That is a big deal. And even though I'll hear mothers say, ‘I feel so guilty, now my daughter has this,' now, I've never heard a daughter come and say, ‘Gosh, I wish my mom hadn't had me because of this.' There's a lot of feeling and emotion that goes on with that, and realize that those individuals are probably going to have fairly complicated management that goes over and above their breast cancer.” TS 41:50
“We know that some women are going to get called back. And it's just because usually they can't see something clearly enough. And so in most cases, those women are going to get cleared with one or two images, and they're going to say, ‘Oh, we compress that better, we checked it with an ultrasound, we're fine.' That woman can go ahead and go. But we don't want to miss those early breast cancers,” Suzanne Mahon, DNS, RN, AOCN®, AGN-BC, FAAN, professor emeritus at Saint Louis University in Missouri, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about what oncology nurses need to know about breast cancer diagnosis. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by January 31, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to breast cancer diagnostic considerations. Episode Notes Complete this evaluation for free NCPD. Previous ONS Podcast™ site-specific episodes: Episode 345: Breast Cancer Screening, Detection, and Disparities ONS Voice articles: An Oncology Nurse's Guide to Cascade Testing Breast Cancer Prevention, Screening, Diagnosis, Treatment, Side Effect, and Survivorship Considerations ONS books: Breast Care Certification Review (second edition) Guide to Breast Care for Oncology Nurses ONS courses: Breast Cancer Bundle Breast Cancer: Prevention, Detection, and Pathophysiology ONS Biomarker Database results for breast cancer ONS Learning Libraries: Breast Cancer Genomics and Precision Oncology American Cancer Society: Early Detection and Diagnosis Breast Cancer Facts and Figures Your Breast Pathology Report: Breast Cancer National Comprehensive Cancer Network National Cancer Institute Breast Cancer—Patient Version To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “When a woman gets a callback, that is incredibly anxiety provoking, because they're very scared and they don't know what it means. And I think that's a place where oncology nurses can remind—if it's patients or friends who are asking—that just because you have a call back, doesn't mean you have a malignancy.” TS 8:16 “We also know that when we call somebody back, that's very scary and anxiety provoking. And we don't want to subject women to unnecessary anxiety and stress through the procedure. And if it's too stressful, they won't come back again. That is actually a big harm that we don't want to occur. That's considered an acceptable amount. So we know that some women are going to get called back, and it's just because usually they can't see something clearly enough.” TS 11:26 “I think one of the most important things is to really help that woman understand the biopsy report. So now everybody, with most of the electronic medical records, that woman seeing that biopsy result—maybe before her provider is seeing it, depending on whether they get a chance to call that individual. But, you know, they could get a notification in their medical record, or a new report is available, and they can click on there and they could be looking at something that is very scary, not necessarily a good time, you know, like they're getting ready to do something. And so that is a problem overall with sometimes getting bad news in oncology.” TS 15:09 “Sometimes it's really good [for patients to bring] someone who can just be that set of ears or who can answer those questions, who's emotionally involved but maybe not so emotionally involved, if that makes sense. And I think that that is something we can really encourage people to identify that person who's going to really be able to support them.” TS 16:42 “When we approach a pathology report, the patient, you know, if they open that on their own, they're just going to see breast carcinoma, or they aren't going to look at all of the details of it. They can be quite overwhelming to look at. But I think that it's important to kind of take the patient through it, step by step, and realize that it's often a case of repeated measures—that you might do it and then you might do it again the next day or a day later.” TS 20:55 “Breast cancer care has changed so much over the past few decades. And I think people forget, you know, I've been in the business a long time, but years ago, everybody kind of got the same treatment if they got diagnosed. And we now understand so much about breast cancer treatment, but I think that has come on the shoulders of so, so, so many women who have enrolled in clinical trials to help us understand pathology better, to help us understand the impact of certain treatments. And so I think, first of all, we need to thank those women who have generously contributed to this base of knowledge. And it's a place where those clinical trials have really made a difference.” TS 35:46
“The statistic you always kind of want to keep in the back of your brain is that over a lifetime, one in eight women will be diagnosed with breast cancer. So that means for an individual assigned female at birth, there's a 13% chance that if that individual lives to age 85, that they will be diagnosed with breast cancer. So, it's the most common cancer diagnosed in this group,” Suzanne Mahon, DNS, RN, AOCN®, AGN-BC, FAAN, professor emeritus at Saint Louis University in St. Louis, MO, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about breast cancer screening. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by January 10, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to breast cancer screening, detection, and disparities. Episode Notes Complete this evaluation for free NCPD. ONS Podcast™ episodes: Episode 333: Pharmacology 101: CDK Inhibitors Episode 316: Pharmacology 101: Estrogen-Targeting Therapies ONS Voice articles: An Oncology Nurse's Guide to Cascade Testing Breast Cancer Prevention, Screening, Diagnosis, Treatment, Side Effect, and Survivorship Considerations Encourage Breast Cancer Screening in Childhood Cancer Survivors Genetic Disorder Reference Sheet: BARD1 Genetic Disorder Reference Sheet: BRCA1 and BRCA2 Hereditary Cancers Genetic Disorder Reference Sheet: PALB2 ONS books: Breast Care Certification Review (second edition) Guide to Breast Care for Oncology Nurses Clinical Journal of Oncology Nursing article: Germline Cancer Genetic Counseling: Clinical Care for Transgender and Nonbinary Individuals ONS courses: Breast Cancer Bundle Breast Cancer: Prevention, Detection, and Pathophysiology ONS Learning Library: Genomics and Precision Oncology American Cancer Society Breast Cancer Facts and Figures Breast Cancer Risk Assessment Calculator Breast Cancer Risk Assessment Tool National Comprehensive Cancer Network Tyrer-Cuzick Risk Assessment Calculator To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “Unfortunately, probably about 42,500 women die every year from breast cancer, and that number still seems really high because mammography screening has really enabled us to detect breast cancer in many, many cases when it would be most treatable. And so that's a place where you would like to see some real progress.” TS 3:32 “Primary prevention for all individuals, which is always best to prevent, would include 150 minutes of intentional exercise, watching the diet, keeping that weight as low as possible—we want more muscle and less fat mass—and limiting alcohol intake. Then we go and we talk about screening.” TS 7:29 “The most recent statistic, and this kind of is post-COVID, is that 67% of women age 40 and over have had breast cancer screening in the last two years, which means that there's a hunk of women, 33% of women who have not had breast cancer screening in the last two years and that who are 40 and over. And that to me is a really, really sad statistic because that's a missed opportunity for screening.” TS 11:32 “Sometimes we forget that women and individuals who've had breast cancer, especially if they had it at a younger age, their risk of a second breast cancer over time is about 1% or 2% per year. So, if you have a first breast cancer at 40, and you live another 30 years, two times 30 is 60, that risk is substantial. A lot of times we don't see as much anymore, which is good. Individuals who had a lot of radiation to the chest, we used to see a lot of young individuals having radiation therapy for Hodgkin's disease that encompassed the chest, and a lot of them were diagnosed with breast cancer afterwards.” TS 15:31 “One of the things that always makes me really sad is that probably less than 40% of people who are eligible for this cascade testing, and mind you, many of the laboratories, if we test a parent and say they have a pathogenic variant, they will offer free testing to relatives for 90–120 days in that lab. They don't even have to pay for the genetic test. They just have to get the counseling and send it. But less than 40% of individuals who would benefit from cascade testing ever get it done.” TS 35:02 “I have had this privilege of sitting for decades watching genetics. That's the only area I've ever worked in that is always completely changing. And just when you think you got it, there is something new and it's really driving our oncology care. And I would really encourage people, I know we've said it about 10 times now, to look at that Genomics and Precision Medicine Learning Library, there are resources in there if you want to spend 3 minutes, 5 minutes, 10 minutes—if you got a whole hour or two, there's courses. There are so many things in there, and if you really want to become more savvy, you can, and that's a great place to start.” TS 45:34
“Who would think that we would be here 50 years later? And with the excitement that I think will build even more, I'm so humbled and honored to talk to young nurses. And their excitement—the same excitement that we had in the very beginning—is inherent. I hope that our legacy will be that we are able to pass on this tremendous gift of our careers to new nurses,” Cindi Cantril, MPH, RN, OCN®-Emeritus, founding ONS member and first vice president, told Darcy Burbage, DNP, RN, AOCN®, CBCN®, chair of the ONS 50th Anniversary Committee, during a conversation about the history of ONS's inception. Burbage spoke with Cantril and Connie Henke Yarbro, MS, RN, FAAN, founding ONS member and first treasurer, about the inspirational nurses who started the organization and its impact over the past 50 years. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Episode Notes NCPD contact hours are not available for this episode. ONS Podcast™ episodes: Episode 337: Meet the ONS Board of Directors: Haynes, Wilson, and Yackzan Episode 258: ONS Through the Ages: Stories From the Early Days With Cindi Cantril and George Hill ONS Voice articles: Connie Henke Yarbro Oncology Nursing History Center Commemorates the Legacy of Oncology Nurses Nurses Empower Change Through Leadership and Advocacy Roles Seeds Planted Today Nurture a Harvest of Future Generations of Oncology Nurses ONS's Success Is Our Success Connie Henke Yarbro Oncology Nursing History Center ONS Mission, Vision, and Values Oncology Nursing Foundation Clinical Journal of Oncology Nursing article: Supporting One Another for 40 Years To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode Yarbro: “In 1973, there was really kind of the first nursing conference for oncology nurses in Chicago. At that conference, Lisa Begg Marino and Shirlee Koons, myself, and about 20 nurses met to discuss how we could identify each other and that we needed to communicate because we were really each isolated in our own separate cancer center or clinic.” TS 2:09 Cantril: “What's interesting is that I contacted a lawyer in St. Louis and told him what we were trying to do, and the comment was shocking at the time. And he said, ‘Well, you know, you really could have your own autonomy. It would just cost $25, and you could start your own charter organization.' Little did we know that we would grow to be where we are.” TS 3:50 Yarbro: “I was with medical oncology, and you [Cindi] were with surgeons, so we were really all defining our roles. At that time, I was medical oncology, and I would travel the state of Alabama with the medicine to give the Hodgkin's disease patients or children with leukemia their second dose, so they did not have to drive to the medical center because there weren't any oncologists in the community. They were just made at the academic centers. Today, I don't know whether you could get in a car and travel with your vincristine, procarbazine, and all the other medicines.” TS 11:24 Cantril: “How do we facilitate a large, organized fashion and allowing people to have some sort of more intimate autonomy in their own environment? Because let's face it, not every nurse is going to be able to go to Congress. Not every nurse is going to be able to go to a regional meeting. So the chapters really allowed for a wider net for us to identify nurses so invested in cancer nursing.” TS 25:23
“The Leadership Development Committee (LDC) is one of the most important member volunteer positions in the organization, and here's why: The main purpose of the LDC is to recruit, vet, and select ONS Board of Directors. As some of you may know, it has been three years since we moved away from members voting for directors,” ONS member Nancy Houlihan, MA, RN, AOCN®, ONS past president and former director of nursing practice at Memorial Sloan Kettering Cancer Center in New York, NY, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about what it's like to serve on the Leadership Development Committee. The advertising messages in this podcast episode are paid for by Ipsen. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Episode Notes This episode is not eligible for NCPD. Oncology Nursing Podcast™ episodes: Episode 340: What It's Like to Plan an ONS Conference Episode 337: Meet the ONS Board of Directors: Haynes, Wilson, and Yackzan Episode 270: Meet the ONS Board of Directors: Brown, MacIntyre, and Woods Episode 239: Meet the ONS Board of Directors: Allen, Mathey, and Robison Episode 224: Meet the ONS Board of Directors: Nevidjon, Geddie, and Garner Episode 213: Meet the ONS Board of Directors: Brant, Burger, and Knoop Episode 200: Meet the ONS Board of Directors: Houlihan, Ferguson, and Polovich ONS Voice articles: Find Your Voice With ONS's Leadership Development Committee Nursing Leadership Unlocked Nurses Empower Change Through Leadership and Advocacy Roles Think Tank Will Explore Nurse Leadership Development Initiatives ONS course: Board Leadership: Nurses in Governance ONS Volunteer Opportunities ONS Leadership Learning Library Contact the LDC To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an Oncology Nursing Podcast™ Club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “I feel like I have come full circle, developing my knowledge and leadership skills over 25 years, both at ONS and in my professional career, applying them to ONS leadership as a director and an officer, and then transferring that knowledge to work with a diverse team of ONS members on the LDC to build the best slate of directors.” TS 3:52 “There's an annual review and editing of processes based on experience and discussion with board leadership and a review of the [notification of intent] and full applications of candidates for the board of directors. As you can imagine, reviewing the notifications of intent packages and the full applications, references, and interviews is very time consuming and requires significant at home and meeting time to complete. The application process is rigorous. The LDC members are the stewards of that work, ensuring fairness and ending with the best possible board of directors.” TS 6:22 Each member of the LDC recognizes the importance of their role in identifying future leaders. They regularly interact with chapter members and leaders and others to relay the opportunities and processes for leadership roles, as I mentioned already, the LDC annually offers Round Table sessions at Congress and bridge. They are advertised to appeal to nurses with an interest in leadership in general, as well as at ONS.” TS 8:28 “An important component to this role is meeting the diversity needs on the board, and every effort is made to ensure that our net is cast wide and is inclusive, while the skill set for board service is at a higher level, we uphold ONS principles relative to belonging and look for an inclusive compliment of directors.” TS 9:33 “Frequently, the LDC works with qualified candidates who opt to wait to move forward because of work commitments, graduate school demands, or family concerns and come back when their lives are more settled, enough to take on the commitments of ONS. Support of employers is a required part of the application for the LDC and the board of directors, since time away from work can be challenging. However, many employees see ONS affiliation as a positive for their organization and are willing to engage in discussions with you about how to make a leadership role possible with your work responsibilities.” TS 10:28 “Historically, there has been a misconception that you can't ‘break into ONS leadership.' I have served the last four years, and my experience has been that we are always looking for new qualified thought leaders from every possible group that ONS serves. For example, we track what worksites our leaders come from so that we have every subspecialty's voice over time.” TS 16:27 “Bottom line is, ONS needs you. Don't be shy to try. The door is open to discuss, and the right opportunity could be available.” TS 17:00 “I am constantly reminded about how smart and influential nurses are and how much they have to contribute. Working with an organization like ONS that unites you with others around a common purpose is very powerful.” TS 17:15 “You know, ONS needs leaders; we're always looking to talk with people about what their interests and strengths are and how they can develop some of those strengths through various volunteer activities.” TS 18:39
In this episode of "WCG Talks Trials," host Geoffrey Schick, director of strategic site partnerships, WCG, is joined by fellow MAGI@home 2024 speakers Sandy Smith, Jess Thompson, and Wesley Warren. They share their unique perspectives and key takeaways from this year's virtual conference, including discussions on contract negotiations, the evolving role of advanced practice practitioners, and the collaborative panels featuring both site and sponsor/CRO insights. The episode also recaps the impactful session on the FDA's Diversity Action Plan and what it means for the future of clinical trials. Tune in to hear about the dynamic energy, valuable connections, and innovative challenges that make MAGI and MAGI@home standout events in clinical research. Don't miss out on the exciting plans for MAGI 2025 in Boston, where trends will continue to evolve and new opportunities will emerge. Guests: Geoffrey Schick, MBA, CHRC, Director of Strategic Site Partnerships, WCG Sandy Smith, RN, MSN, AOCN, Senior Vice President, Clinical Solutions & Strategic Partnerships, WCG Jess Thompson, MS, MBA, PMP, Founder, ACRPM.org Wesley Warren, J.D., Executive Director, Research Strategy & Partnerships, City of Hope
“The gravity of the responsibility was realized when you walked into the boardroom and you're there to make decisions, and the perspective you have to take shifts. Of course, I bring to the table my expertise and my perspective, but the decision-making and strategy behind it is really geared at sustaining the organization and moving us towards our mission, which is to advance excellence in oncology nursing and quality cancer care. Being able to reframe your perspective a little bit around those decisions is something that you don't realize until you're there to do that,” ONS director-at-large Ryne Wilson, DNP, RN, OCN®, told Brenda Nevidjon, MSN, RN, FAAN, chief executive officer at ONS, during a conversation with the three new 2024–2027 directors-at-large on the ONS Board. Nevidjon spoke with Wilson, Heidi Haynes, MN, CRNP, OCN®, and Susan Yackzan, PhD, APRN, AOCN®, about their careers, paths to serving on the Board, and passions in oncology. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by November 15, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: The learner will report an increase in knowledge related to the key roles of the ONS Board of Directors. Episode Notes Complete this evaluation for free NCPD. Oncology Nursing Podcast™ episodes: Episode 270: Meet the ONS Board of Directors: Brown, MacIntyre, and Woods Episode 239: Meet the ONS Board of Directors: Allen, Mathey, and Robison Episode 224: Meet the ONS Board of Directors: Nevidjon, Geddie, and Garner Episode 213: Meet the ONS Board of Directors: Brant, Burger, and Knoop Episode 200: Meet the ONS Board of Directors: Houlihan, Ferguson, and Polovich ONS Voice articles: Climate Change Is Contributing to the Cancer Burden, and Nurses Must Take Action Mentorships Open Opportunities for Oncology Nurses' Career Growth and Wellness Oncology Nurse Joins Panel to Discuss Solutions to Advance Equitable Cancer Care for the LGBTQ+ Community Seeds Planted Today Nurture a Harvest of Future Generations of Oncology Nurses Find Your Voice With ONS's Leadership Development Committee ONS courses: Advocacy 101: Making a Difference A Guide to Chapter Leadership: Chapter President Training A Guide to Chapter Finances: Chapter Treasurer Training Board Leadership: Nurses in Governance ONS Leadership ONS Leadership Learning Library ONS Network and Advocacy Resources Joint Position Statement from APHON, CANO/ACIO, and ONS Regarding Fertility Preservation in Individuals with Cancer To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an Oncology Nursing Podcast Club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode Wilson: “After graduating and moving to Minnesota, I immediately joined the Southeast Minnesota chapter of the Oncology Nursing Society and served on the board and a few different positions, as membership chair and as the legislative liaison for the chapter, as well. And I had the opportunity to go to my first ONS Congress®. That really opened my eyes to all of the possibilities and all the really incredible work that so many of our colleagues across the country have been doing, which really was inspiring and really made me want to do more. I took on more volunteer opportunities within society—things like the OCN® Passing Score Task Force with ONCC, as a Biomarker Database expert reviewer, the Symptom Intervention Guidelines reviewer, and several other volunteer opportunities, just to stay connected and build relationships, but also give back to the profession that had really given so much to me.” TS 10:06 Haynes: “What I've been learning is how to transfer that passion and leadership experience that I learned at the local level and grow them into bigger-picture skills, sort of switching my hat and supporting our oncology nurses on more of a global level. I would say for those interested in a national Board position but unsure how they would navigate being new to the role, I can tell you the personal support of the new Board members has been wonderful. Brenda, you and the more senior members of the Board and the National ONS team have all been welcoming and willingly share their knowledge. We even get assigned a Board buddy, and I have to give a shoutout to my Board buddy, Trey Woods, who has graciously—more than graciously—put up with all of my questions and pestering along the way.” TS 16:39 Yackzan: “Well, the health of the organization is a responsibility. So that's what you're giving yourself over to and the task. The chapter board is just on a much more local and scaled back level. I mean this reaches a different proportion. So, you know, it's not that it was the prior. I just think the full impact of it sort of comes to you when you're in the Board meeting and you're thinking through those things. The budget committee is one of the committees that I'm on, and I'm happy to report that we're very healthy. And that's because of the great stewards who came before me, and so, like everybody else on the Board, we feel the impact of making sure that that continues because oncology nursing is essential. We must continue to go forward.” TS 18:18
“There is an old saying that if you ignore your teeth, they'll go away. I think that's a true, true statement. People may think they can get away without daily hygiene. I think that's kind of important, that you should at least get your teeth taken care of at least once or twice a day by brushing and flossing. I mean this has been proven. Our dental people have really taken the lead on preventive care with oral hygiene in that respect,” Raymond Scarpa, DNP, APN-C, AOCN® clinical program manager of head and neck oncology and supervisory advanced practice nurse in the department of otolaryngology at the Rutgers Cancer Institute of New Jersey at University Hospital in Newark,told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about the importance of oral health for patients with cancer. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by October 25, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to oral care for patients with cancer. Episode Notes Complete this evaluation for free NCPD. Oncology Nursing Podcast™ episodes: Episode 269: Cancer Symptom Management Basics: Gastrointestinal Complications Episode 116: Screen and Manage Malnutrition in Patients With Cancer ONS Voice articles: Manage Late Effects From HPV-Positive Oropharyngeal Cancers Nursing Considerations for Head and Neck Cancer Survivorship Care Research Shows That Vaping Alters Mouth Microbes The Case of the Missing Oral Mucositis What Advanced Practice Providers Need to Know About Oral Mucositis ONS book: Clinical Manual for the Oncology Advanced Practice Nurse (Fourth Edition) ONS course: Introduction to Nutrition in Cancer Care Clinical Journal of Oncology Nursing articles: Dental Care: Unmet Oral Needs of Patients With Cancer and Survivors HPV-Positive Oropharyngeal Cancer: The Nurse's Role in Patient Management of Treatment-Related Sequelae Low-Level Laser Therapy: A Literature Review of the Prevention and Reduction of Oral Mucositis in Patients Undergoing Stem Cell Transplantation ONS Symptom Interventions: Mucositis American Cancer Society Oral Cavity (Mouth) and Oropharyngeal (Throat) Cancer Palliative Treatment for Oral Cavity and Oropharyngeal Cancer Head and Neck Cancer Alliance To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an Oncology Nursing Podcast Club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “Radiation, with or without a combination of chemotherapy, can lead to xerostomia, which is like a dry mouth. When this occurs, there's reduced or even absent salivary flow. When this happens, it can lead to mucositis, which is a very painful swelling of the mucous membranes in the oral cavity. This increases the risk of infection and compromises speaking, chewing, and swallowing. Certain chemotherapeutic agents can also accelerate and increase the severity of these side effects.” TS 3:54 “I think pretreatment of the oral cavity prior to starting any of these treatments is a key to managing some of the side effects that can occur. This includes a referral to the dentist for any kind of extractions and removal of any nonviable dentation, along with providing some what they call fluoride treatments. The nurses can also influence the patient by helping them with their nutrition. It's important for them to continue to try to swallow despite some of the side effects that can cause the discomfort in swallowing.” TS 6:53 “I always encourage [patients] to try to use soft-bristle toothbrushes, [water flossers] if necessary, soft foods, nonspicy foods, foods with moderate temperatures. … Try to make sure that they have enough lubrication to get the nutrition they need by including some gravies or sauces or water to help them swallow when their saliva is altered due to these side effects from the treatments.” TS 10:18 “I've been working in the head and neck cancer field for quite some time, and over the years, I've come to realize that this is probably one of the most devastating types of malignancies that someone has. … Head and neck cancer and oral cancers—they affect your basic survival needs. They affect your ability to communicate. They affect your ability to take in nutrition. They can affect your ability to breathe and certainly affect when someone looks at you. It's right there. It's staring them in the face. You can see the side effects of their treatments.” TS 22:41
“CDK4/6 inhibition is considered to be a milestone in the realm of targeted breast cancer therapy. The combination of CDK4/6 inhibitors with the endocrine therapy has really emerged as the foremost therapeutic modality for patients diagnosed with hormone receptor–positive, HER2-negative, advanced breast cancer,” ONS member Teresa Knoop, MSN, RN, AOCN®-emeritus, independent nurse consultant in Nashville, TN, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during the latest episode in our series about anticancer drug classes. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by October 18, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to CDK inhibitors. Episode Notes Complete this evaluation for free NCPD. Oncology Nursing Podcast™ episodes: Pharmacology 101 series Episode 329: Pharmacology 101: BRAF Inhibitors Episode 313: Cancer Symptom Management Basics: Other Pulmonary Complications Episode 295: Cancer Symptom Management Basics: Pulmonary Embolism, Pneumonitis, and Pleural Effusion Episode 80: Patients Need Checkpoint Inhibitor Education Episode 5: New Guidelines for Managing Immunotherapy-Related Adverse Events ONS Voice articles: Combination CDK4/6 and Fulvestrant Has Survival Benefits in Late-Stage Breast Cancer FDA Approves Inavolisib With Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA-Variant, HR-Positive, HER2-Negative, Advanced Breast Cancer FDA Approves Ribociclib With an Aromatase Inhibitor and Ribociclib and Letrozole Co-Pack for Early High-Risk Breast Cancer FDA Expands Early Breast Cancer Indication for Abemaciclib With Endocrine Therapy FDA Warns of Rare Lung Inflammation With Certain CDK4/6 Inhibitors Manage Immunotherapy-Related Diarrhea and Colitis Oncology Drug Reference Sheet: Ribociclib The Case of the CTCAE Assessment for CDK4/6 Adverse Events ONS book: Clinical Guide to Antineoplastic Therapy: A Chemotherapy Handbook (fourth edition) Clinical Journal of Oncology Nursing article: Targeted Therapies: Treatment Options for Patients With Metastatic Breast Cancer ONS Symptom Intervention: Prevention of Infection: General ONS Breast Cancer Learning Library ONS CDK4/6 Administration Checklist ONS Oral Anticancer Medication Toolkit Breastcancer.org Susan G. Komen: CDK4/6 Inhibitors Ibrance® (palbociclib) patient site Kisqali® (ribociclib) patient site Verzenio® (abemaciclib) patient site To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an Oncology Nursing Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “Common toxicity among this class of agents are things like nausea/vomiting, diarrhea, fatigue. All three are associated with low white blood cell counts, which we know as neutropenia, which can cause an increased risk of infection.” TS 10:46 “All three of these CDK4/6 inhibitors are pills taken by mouth, and in most cases they're all given along with endocrine therapy treatments. So, patients will be taking more than one drug. Teach patients how they will take their medication. And the frequency among the three drugs may vary.” TS 13:33 “Patients and caregivers need to know the time of day to take the pills, whether they need to be taken with or without food, or what to do if they miss a dose. We need to help them with a system for organizing the medications. They may find it helpful to use a pill organizer or set reminders on their smartphone, their smartwatch, their computer.” TS 14:29 “Pharmacy and nursing, in my experience, collaborate greatly by determining those drug–drug and drug–food interactions. It is so crucial in determining those interactions and educating our patients because we have to remind patients at each appointment and review these drugs and foods and other things they may be taking, at each appointment. And that often can be done by either pharmacists or nurses or both in collaboration.” TS 23:29 “This class of drug is generally well-tolerated, and I do want nurses to know that that we can help patients with these side effects. And they are generally well-tolerated with appropriate management.” TS 30:55
82: Uplifting Messages from the Universe! Annie Jones PhD, MBA, MSN, RN, AOCN, NC-BC Highlights“I thank the universe and have much gratitude. I think what's on my heart is that community is so important. And it's our own responsibility for ourselves, and to remember that when we see another member of our community— so in other words, our Nursing group, our Nurse coaches in particular— is that we're a sister and brotherhood, and we have to reach out to keep ourselves together in a world that is designed, at the moment, to tear us from all ends.” ~ Annie Jones PhD, MBA, MSN, RN, AOCN, NC-BCAh Ha MomentsThe universe is always supporting you. Giving you what you need and who you need to elevate you and sustain you towards whatever you desire.Life will take you on many twists and turns and the universe will guide you.You will be faced with challenges and possibilities, and you get to choose. Maybe you even become a Possibilitarian!Listen to the messages the universe is sending you.Links and ResourcesIntegrative Nurse Coaches in ACTION! podcastBarbara Dossey's websiteHarmony HillBonney & Richard Schaub - Transpersonal Nurse CoachingHealth Forward LLCAnnie's LinkedInHarmony Hill in Union, WA Wings of Hope*****Integrative Nurse Coach Academy I Integrative Nurse Coach FoundationWe provide nurses with a global community for learning, networking, and reconnecting. Thank you for listening. We LOVE Nurses! Please leave us a 5 star rating and a positive comment about an episode you love! Follow Integrative Nurse Coach Academy on Facebook, Instagram, LinkedIn Learn more about our programs at the Integrative Nurse Coach Academy Schedule a free call with one of our awesome admissions specialists here>> and get your questions answered!
“Instead of creating silos, how can we work together, create networks, and elaborate more in the future? Because we have such a robust wealth of knowledge and expertise, that ONS is very good at helping to facilitate that,” Jan Tipton, DNP, APRN-CNS, AOCN®, clinical assistant professor in the School of Nursing at Purdue University in West Lafayette, IN, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about her volunteer experience in a think tank held during the 2024 ONS Congress®. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.25 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at myoutcomes.ons.org by August 2, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of NCPD by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to participation in professional collaboration opportunities. Episode Notes Complete this evaluation for free NCPD. Volunteer Opportunities on ONS Communities Oncology Nursing Podcast episodes: Episode 320: What It's Like to Be a Peer Reviewer or Associate Editor for an ONS Journal Episode 309: What Brings You to ONS Congress®? ONS Voice articles: What Brings You Value in ONS? You Can Thank a Volunteer for That The Power of Connection in Oncology Nursing ONS Health Policy Priorities and Agenda ONS Resources for Researchers Luma Institute: Abstraction laddering American Organization of Nursing Leadership think tanks National Association of Clinical Nurse Specialists health policy think tanks To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an Oncology Nursing Podcast™ Club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “Individuals that would be helpful for this type of think tank would be those that view themselves as change agents, those who are willing and motivated to confront uncomfortable truths, persistent issues, that might think of a better way to do things. In addition, people that are highly inquisitive, curious, eager to learn, and those that have out-of-the-box type thinking, flexible, creative, and would work well in this group environment.” TS 3:29 “We all came from very diverse backgrounds, all over the country, and it was a great opportunity to blend our backgrounds in academia, clinical practice, and then be able to share not only some of the dilemmas and hardships that we see, but then to recommend some actions for the future.” TS 6:12 “But things that sparked my interest were things that were very small scale and then things that were very large scale that everyone could benefit from hearing. And one that comes to mind was, in a very small way, how can we collaborate with our various backgrounds and PhDs and DNPs and have more of a meet-and-greet? We're sometimes in our silos. And how can we create opportunities for each other to learn from each other, to have these meetings, maybe in social venues, to learn about interests, research, collaborations in the future?” TS 6:55 “I think it's important to challenge yourself to be open to new ideas, to keep an open mind. Consider that your idea may not be agreeable to everyone. So to think through, everyone that you may be participating with and have a heightened awareness of all the differences that we may have in our different backgrounds, gender, characteristics that we believe in, in terms of our practice. So thinking through those things in advance and being open to new ideas, I think, is really important and sort of self-reflecting before the event.” TS 15:41
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/ILNA/IPCE information, and to apply for credit, please visit us at PeerView.com/FRR865. CME/MOC/NCPD/ILNA/IPCE credit will be available until May 25, 2025.Ten Steps for Highly Successful Myeloma Care: Guidance on the Road to Remission With Antibodies, BCMA Immunotherapy, and Other Innovations In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Regeneron Pharmaceuticals, Inc., and Sanofi.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/ILNA/IPCE information, and to apply for credit, please visit us at PeerView.com/FRR865. CME/MOC/NCPD/ILNA/IPCE credit will be available until May 25, 2025.Ten Steps for Highly Successful Myeloma Care: Guidance on the Road to Remission With Antibodies, BCMA Immunotherapy, and Other Innovations In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Regeneron Pharmaceuticals, Inc., and Sanofi.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/ILNA/IPCE information, and to apply for credit, please visit us at PeerView.com/FRR865. CME/MOC/NCPD/ILNA/IPCE credit will be available until May 25, 2025.Ten Steps for Highly Successful Myeloma Care: Guidance on the Road to Remission With Antibodies, BCMA Immunotherapy, and Other Innovations In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Regeneron Pharmaceuticals, Inc., and Sanofi.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/ILNA/IPCE information, and to apply for credit, please visit us at PeerView.com/FRR865. CME/MOC/NCPD/ILNA/IPCE credit will be available until May 25, 2025.Ten Steps for Highly Successful Myeloma Care: Guidance on the Road to Remission With Antibodies, BCMA Immunotherapy, and Other Innovations In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Regeneron Pharmaceuticals, Inc., and Sanofi.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/ILNA/IPCE information, and to apply for credit, please visit us at PeerView.com/FRR865. CME/MOC/NCPD/ILNA/IPCE credit will be available until May 25, 2025.Ten Steps for Highly Successful Myeloma Care: Guidance on the Road to Remission With Antibodies, BCMA Immunotherapy, and Other Innovations In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Regeneron Pharmaceuticals, Inc., and Sanofi.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/ILNA/IPCE information, and to apply for credit, please visit us at PeerView.com/FRR865. CME/MOC/NCPD/ILNA/IPCE credit will be available until May 25, 2025.Ten Steps for Highly Successful Myeloma Care: Guidance on the Road to Remission With Antibodies, BCMA Immunotherapy, and Other Innovations In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Regeneron Pharmaceuticals, Inc., and Sanofi.Disclosure information is available at the beginning of the video presentation.
“What you teach patients about that the side effects may be somewhat different, because it's more of a regional treatment with less systemic toxicities, so it's teaching patients about the drugs, the side effects, and the actual procedure itself,” Lisa Hartkopf-Smith, MS, RN, AOCN®, CHPN, advanced practice nurse at OhioHealth Center in Columbus and ProMedica Cancer Institute in Toledo, OH, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a discussion about the oncology nurse's role in intra-arterial chemotherapy administration. This episode is part of a series about chemotherapy administration, which we'll include a link to in the episode notes. You can earn free NCPD contact hours after listening to this episode and completing the evaluation linked below. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.5 contact hours of nursing continuing professional development (NCPD), which may be applied to the nursing practice, oncology nursing practice, or treatment ILNA categories, by listening to the full recording and completing an evaluation at myoutcomes.ons.org by February 2, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of NCPD by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: The learner will report an increase in knowledge about the nurse's role in intra-arterial chemotherapy administration. Episode Notes Complete this evaluation for free NCPD. Oncology Nursing Podcast: Episode 252: Intraperitoneal Administration: The Oncology Nurse's Role Episode 285: Transarterial Chemoembolization: The Oncology Nurse's Role Additional episodes about chemotherapy administration Clinical Journal of Oncology Nursing article: Evaluation of a Chemotherapy and Medication Education Process for Patients Starting Cancer Treatment ONS Huddle Card: Chemotherapy ONS Courses: ONS Fundamentals of Chemotherapy and Immunotherapy Administration ONS/ONCC Chemotherapy Immunotherapy Administration Certificate™ ONS books: Access Device Guidelines: Recommendations for Nursing Practice and Education (fourth edition) Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From Today's Episode “Intra-arterial chemotherapy has actually been in existence over 70-plus years. It's been around for a long time. There are case reports in the literature as early as 1950 of intra-arterial chemotherapy, one specifically being giving nitrogen mustard, of all things, interactively through a catheter for the treatment of Hodgkin lymphoma.” TS 1:43 “Retinoblastoma is a common indication at this point in time for intra-arterial chemotherapy and has very good success rates. Intra-arterial chemotherapy is also used in liver cancers, whether it's an unresectable liver metastasis from adenocarcinoma of the colon or it's unresectable intrahepatic cholangiocarcinoma, as an another example where it's used. And it can also be used in hepatocellular or HCC carcinoma.” TS 6:36 “Some of the things, like pretreatment, things that the nurse has to look for in any of those are labs and particularly clotting times. You know, to make sure that a PT and an INR and a platelet count was drawn because this patient is going to have a catheter in their artery and frequently will have heparin, so we need to make sure you know what that is.” TS 8:22 “When you're pulling your drug information, your patient drug information sheets, it may not be appropriate to give the Adriamycin® teaching sheet from OncoLink or ChemoCare or ONS because that's generally the side effects of systemic treatment. Whereas if it's going to be given intra-arterially, they are probably not going to have hair loss and mouth sores, and their blood counts may not be affected.” TS 10:36 “In some cases, the nurse may be actually administering the medication, and in other cases they're not going to be actually administering it. So, if you have the situation where that intra-arterial procedure is done, like within the operating room or interventional radiology, then typically the radiologist or another physician will be administering it, but the RN may be in the room. It's often not a chemotherapy-qualified RN, it's often interventional radiology RN, so this is really a group effort between oncology nurses and those interventional radiology nurses and operating room nurses.” TS 12:03 “But in that case, as far as administration, again, it will probably be the physician, but where the nurse can play the role is with all those steps of verification. So, the dual verification process for chemotherapy needs to not just apply when you're giving it ID and an infusion center or inpatient. But it needs to happen in those off sites like interventional radiology in the operating room. So, the nurse in this suite can work and be part of that dual verification process, you know, comparing the orders with the drug and the patient identifiers. The nurse in that type of situation, in interventional radiology or operating room, can help ensure that safe handling occurs because those employees and physicians may not be as familiar with it. So, making sure that you have the PPE gowns the gloves goggles in the correct ways to dispose of it in those suites.” TS 12:43 “With time, just as it would with a venous port, that catheter can move out of place. So, even with the implanted pumps I was mentioning before, those catheters can move, and so we don't routinely check placement of the tip. What can happen is if the tip moves into another place, the patient will have those high doses of chemotherapy going systemic and will experience more side effects.” TS 19:22 “Some part of the adverse reactions could be related to the catheter or the pump itself, and then some of the adverse reactions are related to the drug itself.” TS 20:06 “So, other things that can happen with catheters and pumps, whether they're temporary or permanent, is always the risk for hemorrhage because it's in an artery. So, if something breaks or some tubing becomes disconnected, then the patient could hemorrhage. So, it's important that everything is always lured locked, connections taped, and that is being checked frequently to make sure that everything is tight and secure so that there's not that risk for hemorrhage from a catheter, an IV tubing, or needle becoming disconnected.” TS 21:11 “I honestly think this entire topic is something that's not discussed much, and I wish people knew more about it. I also wish people knew more about one of the areas of this topic—hepatic chemoembolizations, also called TACE [trans-arterial chemoembolization]. There are a lot of patients out there that are getting this in different locations, different hospitals, parts of the country, but because we typically are working in infusion centers are impatient areas, we are often not that knowledgeable about it because it happens somewhere else in interventional radiology or the OR. But our patients are affected by it, and we need to know more about it.” TS 26:55
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/IPCE information, and to apply for credit, please visit us at PeerView.com/NRA865. CME/MOC/NCPD/IPCE credit will be available until November 29, 2024.The A-Team Against Relapsed/Refractory Myeloma: Community Strategies for Enhancing Outcomes With Potent CD38 Antibody Platforms In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerThomas G. Martin, III, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for GlaxoSmithKline and Pfizer.Grant/Research Support from Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; and Sanofi.Faculty/PlannerBeth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Karyopharm Therapeutics; Pfizer; and Sanofi.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/IPCE information, and to apply for credit, please visit us at PeerView.com/NRA865. CME/MOC/NCPD/IPCE credit will be available until November 29, 2024.The A-Team Against Relapsed/Refractory Myeloma: Community Strategies for Enhancing Outcomes With Potent CD38 Antibody Platforms In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerThomas G. Martin, III, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for GlaxoSmithKline and Pfizer.Grant/Research Support from Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; and Sanofi.Faculty/PlannerBeth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Karyopharm Therapeutics; Pfizer; and Sanofi.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/IPCE information, and to apply for credit, please visit us at PeerView.com/NRA865. CME/MOC/NCPD/IPCE credit will be available until November 29, 2024.The A-Team Against Relapsed/Refractory Myeloma: Community Strategies for Enhancing Outcomes With Potent CD38 Antibody Platforms In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerThomas G. Martin, III, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for GlaxoSmithKline and Pfizer.Grant/Research Support from Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; and Sanofi.Faculty/PlannerBeth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Karyopharm Therapeutics; Pfizer; and Sanofi.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/IPCE information, and to apply for credit, please visit us at PeerView.com/NRA865. CME/MOC/NCPD/IPCE credit will be available until November 29, 2024.The A-Team Against Relapsed/Refractory Myeloma: Community Strategies for Enhancing Outcomes With Potent CD38 Antibody Platforms In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerThomas G. Martin, III, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for GlaxoSmithKline and Pfizer.Grant/Research Support from Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; and Sanofi.Faculty/PlannerBeth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Karyopharm Therapeutics; Pfizer; and Sanofi.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/IPCE information, and to apply for credit, please visit us at PeerView.com/NRA865. CME/MOC/NCPD/IPCE credit will be available until November 29, 2024.The A-Team Against Relapsed/Refractory Myeloma: Community Strategies for Enhancing Outcomes With Potent CD38 Antibody Platforms In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerThomas G. Martin, III, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for GlaxoSmithKline and Pfizer.Grant/Research Support from Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; and Sanofi.Faculty/PlannerBeth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Karyopharm Therapeutics; Pfizer; and Sanofi.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CE/CPE/AAPA information, and to apply for credit, please visit us at PeerView.com/BUC865. CME/NCPD/CE/CPE/AAPA credit will be available until December 9, 2024.Antibody–Drug Conjugates, the Ultimate Weapons Against Solid Tumors: Latest Progress, Future Possibilities, and Implications for Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerBeth Sandy, MSN, CRNP, FAPO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc. and Janssen Pharmaceuticals, Inc.Speakers Bureau participant with Amgen Inc.; AstraZeneca; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; and Takeda Pharmaceutical Company Limited.Faculty/PlannerJamie Carroll, APRN, CNP, MSN, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Lilly; Novartis Pharmaceuticals Corporation; Pfizer; Sermonix Pharmaceuticals; and Talzenna.Speakers Bureau participant with Horizon CME and OncLive.Faculty/PlannerElizabeth Prechtel Dunphy, DNP, RN, ANP-BC, AOCN, has a financial interest/relationship or affiliation in the form of:Speakers Bureau participant with Incyte.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CE/CPE/AAPA information, and to apply for credit, please visit us at PeerView.com/BUC865. CME/NCPD/CE/CPE/AAPA credit will be available until December 9, 2024.Antibody–Drug Conjugates, the Ultimate Weapons Against Solid Tumors: Latest Progress, Future Possibilities, and Implications for Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerBeth Sandy, MSN, CRNP, FAPO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc. and Janssen Pharmaceuticals, Inc.Speakers Bureau participant with Amgen Inc.; AstraZeneca; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; and Takeda Pharmaceutical Company Limited.Faculty/PlannerJamie Carroll, APRN, CNP, MSN, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Lilly; Novartis Pharmaceuticals Corporation; Pfizer; Sermonix Pharmaceuticals; and Talzenna.Speakers Bureau participant with Horizon CME and OncLive.Faculty/PlannerElizabeth Prechtel Dunphy, DNP, RN, ANP-BC, AOCN, has a financial interest/relationship or affiliation in the form of:Speakers Bureau participant with Incyte.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CE/CPE/AAPA information, and to apply for credit, please visit us at PeerView.com/BUC865. CME/NCPD/CE/CPE/AAPA credit will be available until December 9, 2024.Antibody–Drug Conjugates, the Ultimate Weapons Against Solid Tumors: Latest Progress, Future Possibilities, and Implications for Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerBeth Sandy, MSN, CRNP, FAPO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc. and Janssen Pharmaceuticals, Inc.Speakers Bureau participant with Amgen Inc.; AstraZeneca; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; and Takeda Pharmaceutical Company Limited.Faculty/PlannerJamie Carroll, APRN, CNP, MSN, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Lilly; Novartis Pharmaceuticals Corporation; Pfizer; Sermonix Pharmaceuticals; and Talzenna.Speakers Bureau participant with Horizon CME and OncLive.Faculty/PlannerElizabeth Prechtel Dunphy, DNP, RN, ANP-BC, AOCN, has a financial interest/relationship or affiliation in the form of:Speakers Bureau participant with Incyte.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CE/CPE/AAPA information, and to apply for credit, please visit us at PeerView.com/BUC865. CME/NCPD/CE/CPE/AAPA credit will be available until December 9, 2024.Antibody–Drug Conjugates, the Ultimate Weapons Against Solid Tumors: Latest Progress, Future Possibilities, and Implications for Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerBeth Sandy, MSN, CRNP, FAPO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc. and Janssen Pharmaceuticals, Inc.Speakers Bureau participant with Amgen Inc.; AstraZeneca; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; and Takeda Pharmaceutical Company Limited.Faculty/PlannerJamie Carroll, APRN, CNP, MSN, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Lilly; Novartis Pharmaceuticals Corporation; Pfizer; Sermonix Pharmaceuticals; and Talzenna.Speakers Bureau participant with Horizon CME and OncLive.Faculty/PlannerElizabeth Prechtel Dunphy, DNP, RN, ANP-BC, AOCN, has a financial interest/relationship or affiliation in the form of:Speakers Bureau participant with Incyte.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CE/CPE/AAPA information, and to apply for credit, please visit us at PeerView.com/BUC865. CME/NCPD/CE/CPE/AAPA credit will be available until December 9, 2024.Antibody–Drug Conjugates, the Ultimate Weapons Against Solid Tumors: Latest Progress, Future Possibilities, and Implications for Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerBeth Sandy, MSN, CRNP, FAPO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc. and Janssen Pharmaceuticals, Inc.Speakers Bureau participant with Amgen Inc.; AstraZeneca; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; and Takeda Pharmaceutical Company Limited.Faculty/PlannerJamie Carroll, APRN, CNP, MSN, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Lilly; Novartis Pharmaceuticals Corporation; Pfizer; Sermonix Pharmaceuticals; and Talzenna.Speakers Bureau participant with Horizon CME and OncLive.Faculty/PlannerElizabeth Prechtel Dunphy, DNP, RN, ANP-BC, AOCN, has a financial interest/relationship or affiliation in the form of:Speakers Bureau participant with Incyte.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CE/CPE/AAPA information, and to apply for credit, please visit us at PeerView.com/BUC865. CME/NCPD/CE/CPE/AAPA credit will be available until December 9, 2024.Antibody–Drug Conjugates, the Ultimate Weapons Against Solid Tumors: Latest Progress, Future Possibilities, and Implications for Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerBeth Sandy, MSN, CRNP, FAPO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc. and Janssen Pharmaceuticals, Inc.Speakers Bureau participant with Amgen Inc.; AstraZeneca; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; and Takeda Pharmaceutical Company Limited.Faculty/PlannerJamie Carroll, APRN, CNP, MSN, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Lilly; Novartis Pharmaceuticals Corporation; Pfizer; Sermonix Pharmaceuticals; and Talzenna.Speakers Bureau participant with Horizon CME and OncLive.Faculty/PlannerElizabeth Prechtel Dunphy, DNP, RN, ANP-BC, AOCN, has a financial interest/relationship or affiliation in the form of:Speakers Bureau participant with Incyte.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CE/CPE/AAPA information, and to apply for credit, please visit us at PeerView.com/BUC865. CME/NCPD/CE/CPE/AAPA credit will be available until December 9, 2024.Antibody–Drug Conjugates, the Ultimate Weapons Against Solid Tumors: Latest Progress, Future Possibilities, and Implications for Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerBeth Sandy, MSN, CRNP, FAPO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc. and Janssen Pharmaceuticals, Inc.Speakers Bureau participant with Amgen Inc.; AstraZeneca; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; and Takeda Pharmaceutical Company Limited.Faculty/PlannerJamie Carroll, APRN, CNP, MSN, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Lilly; Novartis Pharmaceuticals Corporation; Pfizer; Sermonix Pharmaceuticals; and Talzenna.Speakers Bureau participant with Horizon CME and OncLive.Faculty/PlannerElizabeth Prechtel Dunphy, DNP, RN, ANP-BC, AOCN, has a financial interest/relationship or affiliation in the form of:Speakers Bureau participant with Incyte.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Kristen Fessele, PhD, RN, ANP-BC, AOCN a senior […]
Nursing is a 24/7 career. For nurses, getting the schedule you want on or around the holidays is a big deal! Holiday coverage is a big deal for the employers and organizations who are responsible for providing care 24/7. This episode highlights the reality of holiday scheduling and what it can mean for nurses working in hospitals or settings where holiday coverage comes with the job. The Careerwise Nurse podcast is meant for you if you are launching your career, growing into your role, or seeking ways to thrive as a nurse! The Careerwise Nurse podcast is from nurses for nurses. Current and future student nurses - this is for you, too! Support this podcast: Buy me a coffee! FOLLOW the show RATE & REVIEW!! Talk with Natalie about tuning into your best nursing life. Schedule a free introductory coaching call: https://calendly.com/natalie-ditri/careerwisenurse Join the Facebook community - Careerwise Nurse Instagram: Careerwise Nurse Email host Natalie D'Itri, MSN, RN, AOCN
“It's really an exciting time to be in the field of oncology because we can have these specific drugs that target these specific variants rather than, back in the day, when we had to use kind of generic cancer therapies that weren't specific for an individual's cancer,” ONS member Suzanne Walker, PhD, CRNP, AOCN®, senior advanced practice provider and coordinator for thoracic malignancies at the Abramson Cancer Center at Penn Presbyterian Medical Center in Philadelphia, PA, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a discussion about the latest updates in chemotherapy and immunotherapy treatments. Walker is one of the editors of ONS's second edition of the Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice book. You can earn free NCPD contact hours after listening to this episode and completing the evaluation linked below. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.75 contact hours of nursing continuing professional development (NCPD), which may be applied to the treatment ILNA category, by listening to the full recording and completing an evaluation at myoutcomes.ons.org by August 18, 2025. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of NCPD by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: The learner will report an increase in knowledge related to updates in chemotherapy and immunotherapy. Episode Notes Complete this evaluation for free NCPD. Oncology Nursing Podcast: Episode 242: Oncology Pharmacology 2023: Today's Treatments and Tomorrow's Breakthroughs Episode 139: How CAR and Other T Cells Are Revolutionizing Cancer Treatment ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) Clinical Guide to Antineoplastic Therapy: A Chemotherapy Handbook (fourth edition) Guide to Cancer Immunotherapy ONS Biomarker Database ONS courses: ONS/ONCC Chemotherapy Immunotherapy Certificate Course ONS/ONCC Chemotherapy Immunotherapy Certificate Renewal Course Fundamentals of Chemotherapy Immunotherapy Administration Fundamentals of Chemotherapy Immunotherapy Administration Renewal ONS Huddle Cards™️: Antineoplastic Administration Chemotherapy Immunotherapy Targeted Therapy ONS Immuno-Oncology Learning Library ONS Congress® American Cancer Society U.S. Food and Drug Administration (FDA) Oncology Drug Approvals National Cancer Institute National Comprehensive Cancer Network Nature Reviews Drug Discovery article: Trends in the Approval of Cancer Therapies by FDA In the Twenty-First Century OncoLink To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From Today's Episode “We've seen significant improvement in cancer survival over the past one to two decades. And primarily we've seen this not only from reductions in smoking and earlier cancer detection, but advancements in some of our treatments, most notably in the realm of immunotherapy and targeted therapy.” Timestamp (TS) 02:07 “With the discovery of the biomarkers, it has brought around the discovery of genomic-driven therapies that are specific to these biomarkers. That's really changed the landscape of oncology for people that have one of these driver variants.” TS 07:55 “I've definitely seen in my practice where therapy has been completed and, especially for some of these immunotherapy drugs, a couple of months later the patient develops a toxicity that is from the prior immunotherapy. Even chemotherapy can have some long-term toxicities, but we do have to even keep it in mind for immunotherapy that once these drugs are finished, there still could be some long-term side effects. Since they are newer drugs, we still are learning about what some of these long-term toxicities look like.” TS 26:56 “There haven't been a ton of new FDA approvals specific for chemotherapy; however, we have seen chemotherapy still used in practice, particularly in combination with some of these novel therapies. Particularly, we see a lot of chemotherapy and immunotherapy combinations.” TS 27:47
It was just over 12 hours after leaving the OR when I recorded this episode. I had a mastectomy the day before. I had a very short night of sleep and I was still wobbly when I got up in the morning. I had a pretty good memory of getting ready to be wheeled to the OR, being in recovery, and being awakened by the plastic surgeon before 7am on post op day 1. It was a completely novel experience, as is the journey ahead, as I navigate breast cancer life. This is my patient experience, on the flip-side of healthcare. The Careerwise Nurse podcast is meant for you if you are launching your career, growing into your role, or seeking ways to thrive as a nurse! The Careerwise Nurse podcast is from nurses for nurses. Current and future student nurses - this is for you, too! Support this podcast: Buy me a coffee! FOLLOW the show RATE & REVIEW!! Help grow the show to reach more nurses!!! Talk with Natalie about tuning into your best nursing life. Schedule a free introductory coaching call: https://calendly.com/natalie-ditri/careerwisenurse Join the Facebook community - Careerwise Nurse Instagram: Careerwise Nurse Email host Natalie D'Itri, MSN, RN, AOCN
In the first episode of our new podcast series, WCG Talks Trials, we are joined by three industry experts, Lisa Ballance from Virginia Commonwealth University, John Musser from Florida Cancer Specialists and Research Institute, and Dan Otap from Genentech, to discuss the topic of overcoming site challenges and addressing site burden.Listen in as we discuss the results of WCG's recently published 2023 Clinical Research Site Challenges Survey Report, gain insights from our guests on solutions their organizations have implemented to reduce site burden, and share perspectives on how sites, sponsors, and CROs can work to improve site and trial efficiency. Speakers: Sandy Smith, RN, MSN, AOCN Senior Vice President, Clinical Solutions and Strategic Partnerships at WCG ClinicalLisa Richman Balance Associate Vice President for Research Strategy and Regulatory Affairs at Virginia Commonwealth University John Musser Senior Director, Clinical Research Administration at Florida Cancer Specialists & Research InstituteDan Otap Principal, Alliance and Partnerships Lead at Genentech
In this episode of Cancer Registry World, we welcome Sharon Gentry, MSN, RN, HON-ONN-CG, AOCN, CBCN, the Program Director of the Academy of Oncology Nurse and Patient Navigators (AONN+) and the incoming Editor of the Journal of Oncology Navigation and Survivorship (JONS). Our discussion focuses on the role of the oncology nurse and patient navigator and provides valuable tips for navigation research utilizing the cancer registry. Enjoy listening and learning!
It is the day of surgery. This episode describes my pre-operative experience. I arrived 3 hours before I was scheduled to go to surgery. There were several things I needed to do to be ready for the operating room. I refer to some of what I know from work as a nurse and describe much of the unfamiliarity that comes with being a patient and undergoing surgery for the very first time. The Careerwise Nurse podcast is meant for you if you are launching your career, growing into your role, or seeking ways to thrive as a nurse! The Careerwise Nurse podcast is from nurses for nurses. Current and future student nurses - this is for you, too! Support this podcast: Buy me a coffee! FOLLOW the show RATE & REVIEW!! Help grow the show to reach more nurses!!! Talk with Natalie about tuning into your best nursing life. Schedule a free introductory coaching call: https://calendly.com/natalie-ditri/careerwisenurse Join the Facebook community - Careerwise Nurse Instagram: Careerwise Nurse Email host Natalie D'Itri, MSN, RN, AOCN
I did not put breast cancer screening (aside from a routine mammogram) on my 2023 to-do list. I did suddenly become well aware of what the process is over several months this year. The experience of screening and diagnosis continues in this episode. Learn about the activities leading up to surgery. The Careerwise Nurse podcast is meant for you if you are launching your career, growing into your role, or seeking ways to thrive as a nurse! The Careerwise Nurse podcast is from nurses for nurses. Current and future student nurses - this is for you, too! Support this podcast: Buy me a coffee! FOLLOW the show RATE & REVIEW!! Help grow the show to reach more nurses!!! Talk with Natalie about tuning into your best nursing life. Schedule a free introductory coaching call: https://calendly.com/natalie-ditri/careerwisenurse Join the Facebook community - Careerwise Nurse Instagram: Careerwise Nurse Email host Natalie D'Itri, MSN, RN, AOCN
I did not put breast cancer screening (aside from a routine mammogram) on my 2023 to-do list. I found out what happens when your mammogram is abnormal. In this episode, I share my experience as a patient. This journey started in February and continued into June. I had multiple appointments and procedures. Despite being a nurse (oncology nurse) and being well-cared for, there was a lot I did not know in this more in-depth diagnostic process. Learn more in part 3. The Careerwise Nurse podcast is meant for you if you are launching your career, growing into your role, or seeking ways to thrive as a nurse! The Careerwise Nurse podcast is from nurses for nurses. Current and future student nurses - this is for you, too! Buy me a coffee! FOLLOW the show RATE & REVIEW!! Help grow the show to reach more nurses!!! Talk with Natalie about tuning into your best nursing life. Schedule a free introductory coaching call: https://calendly.com/natalie-ditri/careerwisenurse Join the Facebook community - Careerwise Nurse Instagram: Careerwise Nurse Email host Natalie D'Itri, MSN, RN, AOCN
An essential act of well-being, the practice of storytelling creates a social connection that fosters a sense of community and mutual support in both the storyteller and listener. During the Second Annual ONS Storytelling session held at the 48th Annual ONS Congress® in April 2023, ONS members Sarah Lewis, MNE, RN, OCN®, palliative care nurse navigator at Oregon Health and Science University in Portland; Crystal Johnson, RN, BSN, OCN®, patient engagement liaison at Genmab who lives in Ohio; Susie Maloney, MS, APRN, AOCN®, AOCNS®, senior director of the Medical Affairs Company and principal of Oncology Nursing Advisors, LLC, in Dayton, OH; and Brenda Sandoval Tawakelevu, BSN, RN, OCN®, nursing professional development practitioner at the Huntsman Cancer Institute in Salt Lake City, UT, engaged in the practice of storytelling around the theme of renewal in the context of oncology nursing. In this episode, the four oncology nurses share their tales with hosts Anne Ireland, DNP, RN, AOCN®, CENP, and Jaime Weimer, MSN, RN, AGCNS-BC, AOCNS®, oncology clinical specialists at ONS. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at myoutcomes.ons.org by April 28, 2025. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of NCPD by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: The learner will report an increase in knowledge related to how nurses learn from one another through storytelling. Episode Notes Complete this evaluation for free NCPD. Oncology Nursing Podcast episodes: Episode 101: Why We Love Oncology Episode 90: The Year of the Nurse ONS Voice articles: Behind Our Masks, I See You, I Hear You Mrs. Jones Gave Me the ‘Ah-Ha' Moment That Guided My Entire Nursing Career As Oncology Nurses, We Are the Fish Connect With Your Patients on a Human Level as Well as a Healthcare Level Our Patients Give Us Peace in Unexpected Circumstances Beyond the Bedside: Oncology Nurses Have Endless Opportunities in Unexpected Careers Nursing Representation Is Critical in All Industries—Even Those Outside of Health Care Clinical Journal of Oncology Nursing article: How Can Nurses Stay Resilient and Engaged During a Long and Ever-Changing Career Path? ONS books: Continuing the Legacy: More Voices of Oncology Nurses Reflections on COVID-19 and Cancer Care: Stories by Oncology Nurses Reflections on COVID-19 and Cancer Care: Stories by Oncology Nurses (volume 2) ONS Career Development Learning Library To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From Today's Episode Sarah Lewis “An opportunity presented in spring 2021 to join the outpatient palliative care team as a registered nurse and after much careful consideration, I decided to take the leap. It seemed like it was a good time for a change, it seemed like a ‘dream' position, and I knew I could always go back to bone marrow transplant if it didn't work out. I was surprised when so early after I switched positions my decision was affirmed, and my oncology nursing career reinvigorated.” Timestamp (TS) 04:06 “I learned early on in my oncology nursing career the power of education but will always appreciate the real-life lesson my patient taught me that day. It not only reinforced my decision to step into this brand-new role, but it also re-energized my practice and spirit to continue to perform this awesome work we oncology nurses have the privilege to do every day.” TS 06:32 Crystal Johnson “Being an oncology nurse, you inevitably become an extension of your patient's family. Often, we are with our patients throughout every step of their oncologic journey: initial diagnosis, first chemo, symptom management, remission, relapse, progression and, ultimately end-of-life transition.” TS 07:24 “From the moment I cared for my first oncology patient, I knew I had found my calling, but being able to be a part of something and inspire others in a way that is able to reach far greater than the patients I've cared for throughout my career is the reason I continue to show up every single day. Trusting that what we do makes a difference, and we can continue to cultivate a culture of hope within a community that is forever linked together by an unimaginable bond that no one asked to share.” TS 10:44 Susie Maloney “One thing I've learned when teaching in countries with different cultures is that it is important to respect the people and be educated on what their beliefs happen to be. It is not our job to ‘teach them our Western ways.' This can be a challenge, however, particularly when some beliefs or practices are not evidence based.” TS 12:28 “When working in impoverished countries, it is important to consider what is within their achievable means. We would not teach about the latest therapies that are used in the United States if there is no chance of patients having access to such therapies or medications.” TS 15:28 Brenda Sandoval Tawakelevu “Although I have many fond memories or patients and families that I have loved and cared for, I wouldn't be truthful if I didn't tell you I've also had many doubts about oncology nursing during some of the very rough seasons of life that we all experience. I've been at the crossroads, and I have seen the two roads the poet Robert Frost has so beautifully written about. This hasn't occurred just once but many times through the years as I have experienced the highs and the lows of ‘this road less traveled' of oncology nursing.” TS 18:40 “Now, eight years have passed, and I keep going day by day in the wonderful field of oncology. The flames of passion continue to grow, and that passion has been shared with hundreds of students and nurses that have been in my path over the years. I invite each one of you to choose to connect, choose to find your own balance in the field of oncology nursing, choose to heal your own wounds life has left upon you, and most of all, continue to choose oncology nursing.” TS 26:26
I did not put breast cancer screening (aside from a routine mammogram) on my 2023 to-do list. I found out what happens when your mammogram is abnormal. In this episode, I share my experience as a patient. This journey started in February and continued into May. I saw mostly techs and providers, but not many nurses, in the process. There were several calls with schedulers and those who obtained insurance authorization. I had multiple appointments and procedures. Despite being a nurse (oncology nurse) and being well-cared for, there was a lot I did not know in this more in-depth diagnostic process. The Careerwise Nurse podcast is meant for you if you are launching your career, growing into your role, or seeking ways to thrive as a nurse! The Careerwise Nurse podcast is from nurses for nurses. Current and future student nurses - this is for you, too! Support this podcast: Buy me a coffee! FOLLOW the show RATE & REVIEW!! Help grow the show to reach more nurses!!! Talk with Natalie about tuning into your best nursing life. Schedule a free introductory coaching call: https://calendly.com/natalie-ditri/careerwisenurse Join the Facebook community - Careerwise Nurse Instagram: Careerwise Nurse Email host Natalie D'Itri, MSN, RN, AOCN
Go online to PeerView.com/AZG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you updated on the leading advances in CLL care and the role nurses play in ensuring the best outcomes for patients? Find out in this PeerView Nurse MasterClass, where a panel of leading CLL hematology-oncology nurse experts present state-of-the-art evidence supporting the use of highly efficacious targeted strategies in CLL, including covalent and non-covalent BTKi as well as BCL2i. Our experts will also present a rich collection of case examples from nursing practice designed to explore how nurses can be the cornerstone of the management team. This event recorded at the annual ONS Congress was developed in collaboration with the CLL Society and will also feature a patient video testimonial on the nurse–patient relationship and the key role of nurses as patient educators during the therapeutic journey. Get updated on the advances in CLL care and earn NCPD/ILNA credit today! Upon completion of this activity, participants should be better able to: Summarize the latest clinical evidence and guidelines supporting the use of established and emerging targeted and cellular therapies for the management of patients with CLL across several lines of therapy; Implement nursing protocols to optimize the integration of targeted and cellular therapies into personalized management plans for patients with CLL, including via a clinical trial; Provide counseling to patients with CLL on their disease prognosis, differences among agent classes, therapeutic expectations, dosing, and safety considerations; and Address core practical considerations associated with the use of targeted and cellular therapies, such as dosing, scheduling, care coordination, monitoring, and treatment-emergent adverse events
Go online to PeerView.com/SJV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Can you bet on BCMA for your patients with multiple myeloma (MM)? Based on their demonstrated ability to evade resistance to prior agents and induce deep and durable responses, BCMA CAR-T constructs and bispecific antibodies have emerged as core management options for patients with MM progressing on their therapeutic journey. In collaboration with the HealthTree Foundation for Multiple Myeloma, this expert oncology nurse–led activity uses case-based teaching examples to illustrate practical strategies for the delivery of care with BCMA therapeutics while highlighting strategies for patient education and safety management. Each presentation features resources and tools from the HealthTree Foundation for Multiple Myeloma designed to overcome some of the challenges patients face, increase awareness of BCMA-directed options, and foster collaboration between professionals and patients when faced with difficult-to-treat MM cases. Upon completion of this activity, participants should be better able to: Summarize current evidence and guidelines supporting the use of BCMA antibodies and CAR-T cell therapy across the spectrum of multiple myeloma; Implement team strategies to optimize the integration of anti-BCMA therapies, including in the context of a clinical trial, based on diagnostic evaluation, patient-related and disease-related factors, and prior treatment regimens; Provide education to patients on therapeutic expectations with BCMA therapy, delivery of care aspects, and the risk of treatment-emergent adverse events; and Develop team-based strategies to address practical aspects of care when using novel anti-BCMA therapies, including dosing and scheduling, care coordination, supportive care, and management of treatment-related toxicities, including ocular toxicity, CRS, and neurotoxicity, among others
“Just like with anything we do in oncology, a lot of education is required. Nurses and coordinators are critical to start the education and provide effective resources that are reinforced throughout the treatment,” ONS member Beth Faiman, PhD, MSN, APN-BC, AOCN®, BMTCN®, FAAN, FAPO, advanced practice provider at Cleveland Clinic in Ohio, told Lenise Taylor, MN, RN, AOCNS®, BMTCN®, oncology clinical specialist at ONS, during a conversation about how to address knowledge gaps and barriers to practice regarding patients who are preparing for or who have received CAR T-cell therapy for hematologic malignancies. Faiman was one of the content experts for two ONS focus groups on the topic in March 2023. This podcast episode is produced by ONS and supported by funding from Janssen Oncology and Legend Biotech. ONS is solely responsible for the criteria, objectives, content, quality, and scientific integrity of its programs and publications. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Episode Notes NCPD contact hours are not available for this episode. Oncology Nursing Podcast episodes: Episode 1: Experiences With CAR T-Cell Therapy Episode 139: How CAR and Other T Cells Are Revolutionizing Cancer Treatment Episode 176: Oncologic Emergencies 101: Cytokine Release Syndrome ONS Voice articles: Studies Show Best Practices to Manage CAR T-Cell Therapies' irAEs and Improve Outcomes CAR T-Cell Therapy Programs: Essential Elements to Establish a Successful System A Body of Evidence Helps Nurses Manage CAR T-Cell Therapy Toxicities Clinical Journal of Oncology Nursing articles: CAR T-Cell Therapy: Updates in Nursing Management Building a Program: Implications for Infrastructure, Nursing Education, and Training for CAR T-Cell Therapy Management Across Settings: An Ambulatory and Community Perspective for Patients Undergoing CAR T-Cell Therapy in Multiple Care Settings ONS clinical practice resources: Chimeric Antigen Receptor T-Cell Therapy: A Timeline of Events and Adverse Events Cytokine Release Syndrome ONS course: Nursing Considerations for CAR T-Cell Therapy for Patients With Hematologic Malignancies: Patient Education and Symptom Management ONS videos: CAR T-Cell Therapy Cytokine Release Syndrome American Society for Transplantation and Cellular Therapy Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated With Immune Effector Cells International Myeloma Foundation Leukemia and Lymphoma Society Multiple Myeloma Research Foundation New England Journal of Medicine article: Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma Transplantation and Cellular Therapy article: Overcoming Barriers to Referral for Chimeric Antigen Receptor T Cell Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma Learn more about CAR T-cell therapy and risk evaluation and mitigation strategies (REMS). To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From Today's Episode “Just like with anything we do in oncology, there is a lot of education that is required. The same navigators that take care of our patients through the transplant and cellular therapy process, we have similar cellular coordinators that were part of the focus group. These navigators were critical to start the education and provide effective resources that were reinforced throughout the treatment.” Timestamp (TS) 09:00 “The nurses and coordinators play a huge role during the transition of care. Not only do they help with coordinating appointments, but also the scheduling of tests and coordinating with the referring team. I heard a lot in the focus groups about the nurses communicating from inpatient to outpatient, and also coordinating from center to center.” TS 10:22 “Patients can get really nervous when they're feeling sick. I explain it to them like, “You know how you get a flu shot, and you might get a little reaction as we're training your immune system to provide immunity? Well, it's like that, but way worse.' So, you can get really sick feeling and achy from this, and so that psychosocial support is super important.” TS 18:16 “It takes a lot of burden on the patient, caregiver, and the nurse to really be astute to those symptoms and intervene. We do provide wallet cards to patients. We educate the emergency department staff. We also heard about the infection monitoring and caregiver support is absolutely critical. Fortunately, the symptom management has become quite standardized, which really affords the nurses more autonomy to intervene more efficiently.” TS 20:46 “The nurses found for education a teach-back tool to be quite useful. One of the nurses mentioned asking the patient questions such as, ‘What will you do when you have a fever? Tell me what you do,' and “What do you understand from what the doctor just told you?' And so that was just kind of a way that they could go back and forth with the educational process and really understand what the patients understood.” TS 25:46
Colleen returns to the show to share her experience at a new job in PACU, where she has now been working for several months. This position is an outpatient role, avoiding the need to work nights or weekends. It is an opportunity to learn and be supported in the earliest time of practice. Note: Colleen left her first new graduate job after just 4 months. She moved forward in search of a role that supported her transition to practice as a novice RN in a nurse residency. Listen to Careerwise Nurse podcast episodes 22, 23, and 31, to hear Colleen talk about her previous experience as a new graduate RN. Connect with Colleen on Instagram @colleen.anya FOLLOW the show RATE & REVIEW!! Help grow the show to reach more nurses!! Are you looking to get more out of nursing than just a job? The Careerwise Nurse podcast is meant for you if you are launching your career, growing into your role, or seeking ways to thrive as a nurse! The Careerwise Nurse podcast is from nurses for nurses. Current and future student nurses - this is for you, too! Careerwise Nurse is an opportunity to connect with Natalie D'Itri, MSN, RN. Natalie is an experienced nurse, who coaches nurses to live their best nursing life. Support this podcast: Buy me a coffee! Talk with Natalie about tuning into your best nursing life. Schedule a free introductory coaching call: https://calendly.com/natalie-ditri/careerwisenurse Join the Facebook community - Careerwise Nurse Instagram: Careerwise Nurse Email host Natalie D'Itri, MSN, RN, AOCN
“The idea of early palliative care was really a strategy for preventing people from going through unnecessary and unwanted suffering, treatments, and things that were not consistent with their values and preferences. . . . For people who have a serious illness, it's not good to wait until you're facing these very critical decisions. You need to plan upfront,” ONS member Marie Bakitas, DNS, APRN, FAAN, AOCN®, professor and associate dean for research and scholarship at the University of Alabama at Birmingham, told Jaime Weimer, MSN, RN, AGCNS-BC, AOCNS®, oncology clinical specialist at ONS, during a conversation about implementing palliative and supportive care for patients with cancer. You can earn free NCPD contact hours after listening to this episode and completing the evaluation linked below. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at myoutcomes.ons.org by March 17, 2025. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of NCPD by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: The learner will report an increase in knowledge related to palliative care for patients with cancer. Episode Notes: Complete this evaluation for free NCPD. Oncology Nursing Podcast episodes: Episode 41: Advocating for Palliative Care and Hospice Education Episode 135: ELNEC Has Trained More Than One Million Nurses in End-of-Life Care Episode 204: How Radiation Is Used in Palliative Care ONS Voice articles: APRNs Can lead by Example When Integrating Palliative Care in Practice Managing COVID-19 and Cancer Requires Enhanced Palliative Care Skills ELNEC Milestone Marks Transformation of EOL Care for Countless Patients With Cancer Palliative care topic tag ONS Position Statement on Palliative Care for People With Cancer Clinical Journal of Oncology Nursing article: Clinical Oncology Nurse Best Practices: Palliative Care and End-of-Life Conversations Palliative and Supportive Care articles: The Project ENABLE II Randomized Controlled Trial to Improve Palliative Care for Rural Patients With Advanced Cancer: Baseline Findings, Methodological Challenges, and Solutions Developing a “Toolkit” to Measure Implementation of Concurrent Palliative Care in Rural Community Cancer Centers Journal of the American Medical Association article: Effects of a Palliative Care Intervention on Clinical Outcomes in Patients With Advanced Cancer New England Journal of Medicine article: Early Palliative Care for Patients With Metastatic Non–Small-Cell Lung Cancer Book: Charting Your Course: A Life-Long Guide to Health and Compassion End-of-Life Nursing Education Consortium American Society of Clinical Oncology: Palliative Care in Oncology Resources To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From Today's Episode “Now we think of palliative care as really the umbrella—it's a medical specialty, it's a nursing specialty field that you can get certified in. And hospice and comfort care are a subset of palliative care. Think of palliative care as the umbrella, and then toward the very end of life, hospice care—which is often guided by a very limited prognosis time frame of six months or less—and then within hospice care, comfort care is that care that is provided typically at the very end of life.” Timestamp (TS) 03:13 “For us, the idea of early palliative care was really a prevention strategy for preventing people from going through unnecessary and unwanted suffering, treatments, and things that were not consistent with their values and preferences. We took a page out of the childbirth movement playbook and said, ‘If you're pregnant, you don't wait until 8 months and 29 days, to say, ‘Oh, I'm having a baby. Maybe I should think about how to plan for that.'' Similarly, for people who have a serious illness, it's not good to wait until you're facing these very critical decisions. You need to plan up-front. That was the genesis of our program that we call Project ENABLE.” TS 07:18 “ENABLE was about at the time people were diagnosed, meeting them there and helping them to learn skills of symptom management, communication, problem solving, advance care planning. So that when they were ill and facing these issues, they had the skills and preparation to do so.” TS 08:17 “I think the health equity issues are ones that we can overcome. We have to be aware of them. In particular with palliative care, we need to offer these treatments in ways that have been determined to be culturally acceptable.” TS 11:20 “We need to be doing what we call primary palliative care, and that is that every clinician who interacts with an oncology patient who has advanced cancer, metastatic disease, or high symptom burden, has these skills of communication. Oncology nurses are the lead for pain and symptom management. But there are many communication skills that are really important and prioritizing these kinds of conversations and this kind of content being presented at the front end when people are newly diagnosed.” TS 26:34 “I think it's really beneficial for individual nurses to understand to get their own individual information, but I know we all have the need to do quality improvement projects and other kinds of efforts in our clinics and organizations. This might be something that you prioritize for the year: What aspects of palliative care—this extra layer of support—can we provide? . . . We should continue to educate ourselves about the differences and the ways to present and talk about palliative care so that it removes some of the mystery, reduces some of the perceptions. . . and skillfully say, ‘Hey, this is an extra layer of support for you and your family.'” TS 29:46
“It's incumbent on us as nurses to stay informed about these newly approved drugs or new indications in drugs because we're the front line in helping these patients manage adverse events,” Teresa Knoop, MSN, RN, AOCN®, nurse consultant in Nashville, TN, told Jaime Weimer, MSN, RN, AGCNS-BC, AOCNS®, oncology clinical specialist at ONS, during a conversation about the latest updates and approvals in oncology pharmacology. You can earn free NCPD contact hours after listening to this episode and completing the evaluation linked below. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 1 contact hour of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at myoutcomes.ons.org by January 13, 2025. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of NCPD by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Participants will report an increase in knowledge related to the latest updates and approvals in oncology pharmacology. Episode Notes Complete this evaluation for free NCPD. Oncology Nursing Podcast Episode 126: Oncology Clinical Trials and Drug Development ONS Voice articles: S. Food and Drug Administration (FDA) updates Drug reference sheets Predictive and Diagnostic Biomarkers: Identifying Variants Helps Providers Tailor Cancer Surveillance Plans and Treatment Selection Help Patients Understand Biomarker Test Results and Clinical Trials Options Use ClinicalTrials.gov to Find the Right Cancer Research Studies for Your Patients ONS Biomarker Database ONS Genomics and Precision Oncology Learning Library ONS Immuno-Oncology Learning Library ONS Oral Anticancer Medication Learning Library ONS Biosimilars Learning Library ONS Seal of Approval Library Oral Chemotherapy Education Sheets Intravenous Cancer Treatment Education Sheets Clinical Journal of Oncology Nursing article: Clinical Trials: Nursing Roles During the Approval Process and Pharmacovigilance of Biosimilars FDA resources: Drug development and approval process Oncology/hematologic malignancies approval notifications Ongoing cancer accelerated approvals Verified clinical benefit cancer accelerated approvals Withdrawn cancer accelerated approvals Project Renewal Biosimilars review and approval Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.) Project Livin' Label Oncology Center of Excellence To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From Today's Episode “Full approval through the Center for Drug Evaluation and Research (CDER) and FDA means that those drugs have gone through the laboratory testing, human clinical trial testing, and very extensive clinical trials to make sure that they are effective and that the benefits of those drugs outweigh the risks.” TS 02:28 “In 1992, CDER established a new program that would help these drugs get expedited, particularly in life-threatening or serious diseases like cancer. So they established an accelerated approval pathway for these promising therapies. They were hoping to shorten that period of time, and a number of our cancer-fighting drugs have come onto the market through this accelerated approval pathway.” TS 04:29 “When a drug gets an FDA approval, whether it be accelerated or final, then typically they get approved for one, possibly two indications on that first approval. But there are clinical trials ongoing in other diseases and in other indications. So we will then see drugs—after those clinical trials are conducted—taken to CDER for approval for that new indication.” TS 24:02 “The exciting thing for our patients is that new indications often treat more advanced cancers in which you discover a biomarker and could give patients potential treatment options when other options may have been exhausted.” TS 27:43 “It's incumbent on us as nurses to stay informed about these newly approved drugs or new indications in drugs because we're the front line in helping these patients manage adverse events. Many of these drugs are designed so patients have to stay on them for extended periods of time, or at least they get the greatest benefit by staying on it for extended periods of time. Our patient education is key in helping patients do that.” TS 34:50 “In 2023, I think we will continue to see many new drugs that are approved. We will see new indications. I think particularly we will continue to see cellular therapy agents developed—we'll see them gain new indications. I would be willing to forecast that we're going to see more and more of specific immunomodulatory drugs or those antibody drug conjugates—all of those drugs that are designed to treat the cancer in a couple of different ways.” TS 37:29
What is it like to guide a professional association that serves more than 100,000 oncology nurses? ONS Directors-at-Large Deborah “Hutch” Allen, PhD, RN, CNS, FNP-BC, AOCNP®, Kris Mathey, MS, APRN-CNP, AOCNP®, and Jeanene “Gigi” Robison, MSN, APRN, AOCN®, reflect on how their varied nursing backgrounds and ONS experiences help the ONS Board to support a diverse membership during a conversation with ONS Executive Director Lori Brown. They also shared the professional and personal rewards that nurses can reap when getting involved with ONS at any level. You can earn free NCPD contact hours after listening to this episode and completing the evaluation linked below. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at myoutcomes.ons.org by December 23, 2024. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of NCPD by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: The learner will report an increase in knowledge related to oncology nursing leadership opportunities. Episode Notes Complete this evaluation for free NCPD. ONS Leadership Process ONS DEI Commitment Statement Oncology Nursing Podcast episodes: Episode 200: Meet the ONS Board of Directors: Houlihan, Ferguson, and Polovich Episode 213: Meet the ONS Board of Directors: Brant, Burger, and Knoop Episode 224: Meet the ONS Board of Directors: Nevidjon, Geddie, and Garner ONS Voice articles: Journeying Through Life With ONS Find Your Voice With ONS's Leadership Development Committee New Selection Process Supports Diversity on the ONS Board of Directors Nursing Leadership Has Space for Your and Your Goals Nursing Representation Is Critical in All Industries—Even Those Outside of Health Care ONS Leadership Learning Library ONS Strategic Plan Find all the ways to get involved with ONS at every level. Find an ONS chapter near you. To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From Today's Episode Deborah “Hutch” Allen: “The local, national, and making international connections has provided me with a lot of opportunities for networking and opening many new doors for other positions, including considering running for the Board of Directors member-at-large position for ONS this past year. Keep your mind open, be willing to listen, and accept new opportunities.” Timestamp (TS) 21:03 Jeanene “Gigi” Robison: “When we look at people in our lives and they are in leadership positions, whether that be locally or nationally, I think that they are good resource people for us when we have questions about pursuing that same direction.” TS 26:34 Gigi Robison: “Be open minded and think outside of the box. I believe it is crucial to listen to as many people as you can in order to have a diverse perspective.” TS 37:12 Hutch Allen: “I think it's harder to step back and say, ‘I'm not the expert,' but I am a lifelong learner. I love finding that ‘aha!' when I learn how to apply it to my life and into my practice, and I think that's the most important thing of becoming a board member and always saying to our members that I have to step out of myself, keep an open mind, listen, and provide feedback.” TS 38:33 Kris Mathey: “You really never know what you are going to gain from the people around you.” TS 40:47 Kris Mathey: “It takes only one chance to really get to where you're going. And you may fail along the way, but those are all learning experiences that are going to make you stronger.” TS 41:23 Kris Mathey: “My board involvement really fills my bucket and fills my heart and has really given me that extra—on those hard days at work when I just want to scream sometimes, the involvement in this has really made a difference and helps me keep going.” TS 45:38